Michael Doyle is now serving in a new board position at COTA, Inc.

Nov 01, 2018
Board and Executive Moves
Background Information
COTA improves clinical outcomes and reduces wasteful spend in oncology through precise classification of illness and a smarter use of data. They empower oncologists with actionable insights, enable alternative payment models, create national outcomes benchmarks, accelerate drug discovery and approval, and empower patients to make better decisions for their care.